MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 330059 | Name: Vidofludimus calcium
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Vidofludimus, also known as 4SC 101 or SC12267, is a novel orally active and potent DHODH inhibitor. In vitro, 4SC-101 is a potent inhibitor of human DHODH, inhibits lymphocyte proliferation, and uniquely blocks phytohemagglutinin-stimulated IL-17 production by lymphocytes. In vivo, oral administration of 4SC-101 effectively improved both chronic DSS and acute TNBS colitis in mice. 4SC-101 may have potential for the treatment of intestinal inflammation. Dihydroorotate dehydrogenase (DHODH) is a key enzyme involved in pyrimidine biosynthesis. DHODH is a known target for the treatment of autoimmune diseases.

Chemical Structure

Vidofludimus calcium
Vidofludimus calcium
CAS#1354012-90-0 (calcium)

Theoretical Analysis

MedKoo Cat#: 330059

Name: Vidofludimus calcium

CAS#: 1354012-90-0 (calcium)

Chemical Formula: C40H34CaF2N2O8

Exact Mass: 0.0000

Molecular Weight: 748.79

Elemental Analysis: C, 64.16; H, 4.58; Ca, 5.35; F, 5.07; N, 3.74; O, 17.09

Price and Availability

Size Price Availability Quantity
500mg USD 2,850.00 2 months
1g USD 3,850.00 2 months
2g USD 6,450.00 2 months
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
717824-30-1 (free acid) 1354012-90-0 (calcium) 1354013-27-6 (potassium) 2245772-26-1 (sodium) 1354023-23-6 (tris)
Synonym
Vidofludimus calcium; Vidofludimus; 4SC 101; 4SC-101; 4SC101; SC12267; SC-12267; SC 12267; IMU-838; IMU838; IMU 838; IM90838; IM 90838; IM-90838;
IUPAC/Chemical Name
calcium 2-((3-fluoro-3'-methoxy-[1,1'-biphenyl]-4-yl)carbamoyl)cyclopent-1-ene-1-carboxylate
InChi Key
KWSJBFAXOPFZSO-UHFFFAOYSA-L
InChi Code
InChI=1S/2C20H18FNO4.Ca/c2*1-26-14-5-2-4-12(10-14)13-8-9-18(17(21)11-13)22-19(23)15-6-3-7-16(15)20(24)25;/h2*2,4-5,8-11H,3,6-7H2,1H3,(H,22,23)(H,24,25);/q;;+2/p-2
SMILES Code
O=C(C1=C(C(NC2=CC=C(C3=CC=CC(OC)=C3)C=C2F)=O)CCC1)[O-].O=C(C4=C(C(NC5=CC=C(C6=CC=CC(OC)=C6)C=C5F)=O)CCC4)[O-].[Ca+2]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>5 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 748.79 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: D'Haens G, Stardelova KG, Sadiku E, Kizlova N, Skybalo S, Shehovtsova Y, Abramescu M, Vitt D, Kohlhof H, Muehler A. Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis: A Randomized, Placebo-Controlled, Phase 2 Trial. Clin Transl Gastroenterol. 2025 Jan 10. doi: 10.14309/ctg.0000000000000813. Epub ahead of print. PMID: 39791563. 2: Gege C, Hahn F, Wangen C, Häge S, Herrmann A, Uhlig N, Eberlein V, Issmail L, Klopfleisch R, Grunwald T, Marschall M, Kohlhof H, Vitt D. Synthesis and Characterization of DHODH Inhibitors Based on the Vidofludimus Scaffold with Pronounced Anti-SARS-CoV-2 Activity. ChemMedChem. 2024 Oct 1;19(19):e202400292. doi: 10.1002/cmdc.202400292. Epub 2024 Aug 6. PMID: 38887198. 3: Fox RJ, Wiendl H, Wolf C, De Stefano N, Sellner J, Gryb V, Rejdak K, Bozhinov PS, Vitt D, Kohlhof H, Slizgi J, Ondrus M, Sciacca V, Muehler AR; EMPhASIS investigators. Safety and Dose-Response of Vidofludimus Calcium in Relapsing Multiple Sclerosis: Extended Results of a Placebo-Controlled Phase 2 Trial. Neurol Neuroimmunol Neuroinflamm. 2024 May;11(3):e200208. doi: 10.1212/NXI.0000000000200208. Epub 2024 Apr 25. PMID: 38662979; PMCID: PMC11087024. 4: Sriwastava S, Elkhooly M, Amatya S, Shrestha K, Kagzi Y, Bhatia D, Gupta R, Jaiswal S, Lisak RP. Recent advances in the treatment of primary and secondary progressive Multiple Sclerosis. J Neuroimmunol. 2024 May 15;390:578315. doi: 10.1016/j.jneuroim.2024.578315. Epub 2024 Feb 17. PMID: 38554666. 5: Guo H, Liu D, Liu K, Hou Y, Li C, Li Q, Ding X, Verstegen MMA, Zhang J, Wang L, Ding Y, Tang R, Pan X, Zheng K, van der Laan LJW, Pan Q, Wang W. Drug repurposing screen identifies vidofludimus calcium and pyrazofurin as novel chemical entities for the development of hepatitis E interventions. Virol Sin. 2024 Feb;39(1):123-133. doi: 10.1016/j.virs.2023.11.006. Epub 2023 Nov 19. PMID: 37984761; PMCID: PMC10877426. 6: Vietor J, Gege C, Stiller T, Busch R, Schallmayer E, Kohlhof H, Höfner G, Pabel J, Marschner JA, Merk D. Development of a Potent Nurr1 Agonist Tool for In Vivo Applications. J Med Chem. 2023 May 11;66(9):6391-6402. doi: 10.1021/acs.jmedchem.3c00415. Epub 2023 Apr 26. PMID: 37127285; PMCID: PMC10184128. 7: Sharma K, Berry L, Vryonis E, Ali A, Lara B, Noufaily A, Parsons N, Bradley C, Haley B, Tabuso M, Arasaradnam RP. Prospective, randomised, parallel-group, open-label study to evaluate the effectiveness and safety of IMU-838, in combination with oseltamivir, in adults with COVID-19: the IONIC trial protocol. BMJ Open. 2022 Nov 17;12(11):e055205. doi: 10.1136/bmjopen-2021-055205. PMID: 36396307; PMCID: PMC9676417. 8: Vehreschild MJGT, Atanasov P, Yurko K, Oancea C, Popov G, Smesnoi V, Placinta G, Kohlhof H, Vitt D, Peelen E, Mihajlović J, Muehler AR. Safety and Efficacy of Vidofludimus Calcium in Patients Hospitalized with COVID-19: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial. Infect Dis Ther. 2022 Dec;11(6):2159-2176. doi: 10.1007/s40121-022-00690-0. Epub 2022 Oct 15. PMID: 36242741; PMCID: PMC9568890. 9: Fox RJ, Wiendl H, Wolf C, De Stefano N, Sellner J, Gryb V, Rejdak K, Bozhinov PS, Tomakh N, Skrypchenko I, Muehler AR. A double-blind, randomized, placebo- controlled phase 2 trial evaluating the selective dihydroorotate dehydrogenase inhibitor vidofludimus calcium in relapsing-remitting multiple sclerosis. Ann Clin Transl Neurol. 2022 Jul;9(7):977-987. doi: 10.1002/acn3.51574. Epub 2022 Jun 14. PMID: 35698927; PMCID: PMC9268865. 10: Carey EJ, Eaton J, Clayton M, Gossard A, Iqbal S, Ullah H, Zhang N, Butterfield R, Lindor KD. A pilot study of vidofludimus calcium for treatment of primary sclerosing cholangitis. Hepatol Commun. 2022 Jul;6(7):1589-1597. doi: 10.1002/hep4.1926. Epub 2022 Mar 3. PMID: 35238498; PMCID: PMC9234677. 11: Muehler A, Peelen E, Kohlhof H, Gröppel M, Vitt D. Vidofludimus calcium, a next generation DHODH inhibitor for the Treatment of relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2020 Aug;43:102129. doi: 10.1016/j.msard.2020.102129. Epub 2020 May 6. PMID: 32428844. 12: Muehler A, Kohlhof H, Groeppel M, Vitt D. Safety, Tolerability and Pharmacokinetics of Vidofludimus calcium (IMU-838) After Single and Multiple Ascending Oral Doses in Healthy Male Subjects. Eur J Drug Metab Pharmacokinet. 2020 Oct;45(5):557-573. doi: 10.1007/s13318-020-00623-7. PMID: 32361977; PMCID: PMC7511286.

View History

Ilimaquinone

Ilimaquinone